Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.73 |
| ▸ | POLB | P06746 | 2/20 | 0.73 |
| ▸ | TP53 | P04637 | 8/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17585998 | 0.89 | TP53 (0.78) | MAPTPOLBTP53KMT2ASMN1; SMN2 | |
| SCHEMBL17585985 | 0.89 | SMN1; SMN2 (0.84) | MAPTPOLBTP53KMT2ASMN1; SMN2 | |
| SCHEMBL17585999 | 0.88 | MAPT (0.78) | MAPTPOLBTP53KMT2ASMN1; SMN2 | |
| SCHEMBL17585986 | 0.88 | MAPT (0.83) | MAPTPOLBTP53KMT2ASMN1; SMN2 | |
| SCHEMBL18537583 | 0.85 | MAPT (0.91) | MAPTPOLBTP53KMT2ASMN1; SMN2 | |
| SCHEMBL426425 | 0.85 | MAPT (1.00) | MAPTPOLBTP53KMT2ASMN1; SMN2 | |
| SCHEMBL430178 | 0.84 | KMT2A (1.00) | MAPTPOLBTP53KMT2ASMN1; SMN2 | |
| SCHEMBL17586005 | 0.83 | MAPT (0.78) | MAPTPOLBTP53KMT2ASMN1; SMN2 | |
| SCHEMBL17585989 | 0.83 | KMT2A (0.75) | MAPTPOLBTP53KMT2ASMN1; SMN2 | |
| SCHEMBL17585996 | 0.83 | MAPT (0.86) | MAPTPOLBTP53KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160074373-A1 | METHODS AND COMPOSITIONS FOR INHIBITING HUMAN COPPER TRAFFICKING PROTEINS ATOX1 AND CCS | THE UNIVERSITY OF CHICAGO (US) | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160074373-A1 | METHODS AND COMPOSITIONS FOR INHIBITING HUMAN COPPER TRAFFICKING PROTEINS ATOX1 AND CCS | CLINT1, QSOX1, ACOX1 | MAPT 3330/4885POLB 972/4885TP53 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.